-
Most people taking drugs like Ozempic and Wegovy have shed significant pounds. But obesity experts say that roughly 20% of patients — as many as 1 in 5 — may not see robust results with the medications.
-
After developing Type 2 diabetes and having a heart attack in his 40s, Clearwater resident Fabricio Zambrano switched to a plant-based lifestyle.
-
Young people 10 to 19 years old are 1.5 times more likely to be diagnosed with Type 2 diabetes in the six months after having COVID-19.
-
On this episode, Dr. Lisa Iezzoni joins our host, Dr. Joe Sirven, to examine the responsibilities of four-legged health care professionals.
-
New research shows that the number of 12- to 25-year-olds who used the GLP-1 medications climbed from about 8,700 a month in 2020 to 60,000 a month in 2023.
-
The makers of Ozempic and Mounjaro charge charge around $1,000 a month for the drugs, and insurers are reluctant to pick up the tab. Often, low-income patients have to resort to less effective treatments.
-
Host Dr. Joe Sirven and guests identify signs and symptoms of stroke, stroke treatment and lifestyle factors that contribute to the risk of a brain attack.
-
Studies suggest people who take metformin for diabetes may be at lower risk for cancer, heart disease and dementia. Now researchers aim to test if it prevents age-related diseases in healthy people.
-
The European Medicines Agency regulatory committee joins the FDA in saying there's no known tie between the semaglutide obesity drugs and suicide.
-
With artificial intelligence in health care on the rise, eye screenings for diabetic retinopathy are emerging as one of the first proven use cases of AI-based diagnostics in a clinical setting.